Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Antengene Corporation Limited ( (HK:6996) ) has issued an announcement.
Antengene Corporation Limited announced that the China National Medical Products Administration has approved XPOVIO® (selinexor) for the second-line treatment of multiple myeloma in adult patients who have received at least one prior therapy. This approval enhances Antengene’s market positioning in the treatment of hematologic malignancies and expands the availability of its innovative therapies in the Asia Pacific region, potentially benefiting stakeholders by offering a novel treatment option with a unique mechanism of action.
The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a leading commercial-stage, R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative therapeutics for hematologic malignancies and solid tumors. The company has a pipeline of nine oncology assets, including six with global rights and three with rights for the APAC region. Antengene has obtained 31 investigational new drug approvals in the U.S. and Asia and submitted new drug applications in 11 Asia Pacific markets.
YTD Price Performance: 727.69%
Average Trading Volume: 5,292,247
Technical Sentiment Signal: Buy
Current Market Cap: HK$3.41B
For a thorough assessment of 6996 stock, go to TipRanks’ Stock Analysis page.